The U.S. Food and Drug Administration approved Astellas Pharma Inc. and Seattle Genetics Inc.’s experimental drug Padcev to treat advanced bladder cancer, about three months ahead of schedule.
Roche Holding’s Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer.
An experimental drug developed by Seattle Genetics Inc. and Astellas Pharma Inc. led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to presented data.
Johnson & Johnson wins U.S. FDA approval for bladder cancer drug
Advanced bladder cancer, Approvals, Biomarkers, Breakthrough Therapy Designation, FDA, FDA/Regulatory, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Genetic Mutations, New Drug Application (NDA), Pricing, Priority Review, Shares, Side EffectsJohnson & Johnson’s drug Balversa won U.S. approval as the first targeted therapy for advanced bladder cancer, the Food and Drug Administration announced.
